论文部分内容阅读
目的 观察普伐他汀对糖尿病并发高脂血症或混合型高脂血症患者降脂治疗的有效性和安全性。方法 糖尿病并高脂血症或混合型高脂血症患者每日晚间顿服普伐他汀 10mg ,共 6周 ,观察用药前后血浆总胆固醇 (TC)、甘油三酯 (TG)、高密度脂蛋白胆固醇 (HDL -C)、低密度脂蛋白胆固醇 (LDL -C)、丙氨酸氨基转移酶 (ALT)、天门冬氨酸氨基转移酶 (AST)和肌酸激酶 (CK)水平变化。结果 治疗后 6周时TG、TC和LDL -C均较治疗前明显的降低 (P <0 0 1) ,降低度分别为 36 36 %、2 5 95 %和 2 8 6 8% ,而HDL -C显著升高 (P <0 0 1) ,升高率为 15 78% ,治疗前后ALT、AST和CK无明显变化。整个治疗阶段未发生与药物有关的不良反应。结论 普伐他汀对于糖尿病并发高脂血症或混合型高脂血症患者的降脂疗效是有效的安全的
Objective To observe the efficacy and safety of pravastatin on lipid-lowering therapy in patients with diabetes complicated with hyperlipidemia or mixed hyperlipidemia. Methods Patients with diabetes and hyperlipidemia or mixed hyperlipidemia were treated with pravastatin 10 mg daily for 6 weeks. The levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein Cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatine kinase (CK) Results The levels of TG, TC and LDL - C at 6 weeks after treatment were significantly lower than those before treatment (P <0.01), with the reduction rates of 36 36%, 25 95% and 28 8% respectively, C significantly increased (P <0.01), the rate of increase was 15 78%, before and after treatment ALT, AST and CK no significant change. Drug-related adverse events did not occur throughout the treatment period. Conclusions Pravastatin is effective and safe for the lipid-lowering efficacy of diabetes mellitus patients with hyperlipidemia or mixed hyperlipidemia